
Opinion|Videos|May 8, 2025
Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation
Panelists discuss how optimizing tarlatamab administration requires effective multidisciplinary team collaboration, with oncology, pharmacy, neurology, and nursing coordinating on treatment plans, patient monitoring, and adverse event management to ensure consistent, comprehensive care.
Advertisement
Episodes in this series

Summary for Physicians:
Optimizing Coordination for Tarlatamab Administration:
- Multidisciplinary Team (MDT) Collaboration:
- Regular communication between oncology, pharmacy, neurology, and nursing to align on treatment plans.
- Shared care protocols to ensure consistency in patient monitoring, especially for immune-related adverse effects.
- Joint decision-making for pretreatment screening and addressing adverse events promptly.
- Pharmacy Role:
- Ensure proper drug handling and dosing protocols are followed.
- Support with timely drug availability and managing potential supply chain issues.
- Neurology Input:
- Monitor for any neurological symptoms (eg, seizures, encephalopathy) and adjust management as needed.
General Approach:
- Establish clear workflows for patient care, from infusion to follow-up, ensuring all team members are aware of each stage of treatment.
Encourage routine MDT meetings to review patient progress and adapt as necessary.
Advertisement
Related to this article

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.

Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Arturo Loaiza-Bonilla, MD, MSEd, FACP, co-founder of Massive Bio and system-wide chief of hematology and oncology at St. Luke’s, explains how AI is matching patients to clinical trials, where the technology falls short, and why he left academia to build what oncology was missing.

The FDA granted RMAT and fast track designations to prizlon-cel, a CD20/CD19 CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5

